

David Pickar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11347316/publications.pdf>

Version: 2024-02-01

117
papers

8,410
citations

50566

48
h-index

53065

89
g-index

117
all docs

117
docs citations

117
times ranked

5110
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacogenomics of psychiatric drug treatment. <i>Psychiatric Clinics of North America</i> , 2003, 26, 303-321.	0.7	11
2	Effect Size of Symptom Status in Withdrawal of Typical Antipsychotics and Subsequent Clozapine Treatment in Patients With Treatment-Resistant Schizophrenia. <i>American Journal of Psychiatry</i> , 2003, 160, 1133-1138.	4.0	20
3	Amphetamine-Induced Dopamine Release and Post-Synaptic Specific Binding in Patients with Mild Tardive Dyskinesia. <i>Neuropsychopharmacology</i> , 2002, 26, 295-300.	2.8	11
4	Effects of Risperidone on the Peripheral Noradrenergic System in Patients with Schizophrenia A Comparison with Clozapine and Placebo. <i>Neuropsychopharmacology</i> , 2002, 27, 293-300.	2.8	24
5	Pharmacogenomics of psychiatric disorders. <i>Trends in Pharmacological Sciences</i> , 2001, 22, 75-83.	4.0	68
6	Comparison of Ketamine-Induced Thought Disorder in Healthy Volunteers and Thought Disorder in Schizophrenia. <i>American Journal of Psychiatry</i> , 1999, 156, 1646-1649.	4.0	313
7	Mechanism of Peripheral Noradrenergic Stimulation by Clozapine. <i>Neuropsychopharmacology</i> , 1999, 20, 29-34.	2.8	56
8	Effects of Atypical Antipsychotic Drug Treatment on Amphetamine-Induced Striatal Dopamine Release in Patients with Psychotic Disorders. <i>Neuropsychopharmacology</i> , 1999, 20, 340-345.	2.8	17
9	The Brain Metabolic Patterns of Clozapine- and Fluphenazine-Treated Female Patients with Schizophrenia Evidence of a Sex Effect. <i>Neuropsychopharmacology</i> , 1999, 21, 632-640.	2.8	23
10	Predicting Response to Clozapine. <i>CNS Drugs</i> , 1999, 11, 317-326.	2.7	11
11	Abnormalities in the Distributed Network of Sustained Attention Predict Neuroleptic Treatment Response in Schizophrenia. <i>Neuropsychopharmacology</i> , 1998, 19, 36-47.	2.8	38
12	The Apolipoprotein E ϵ 4 Allele Is Associated with Blunting of Ketamine-Induced Psychosis in Schizophrenia A Preliminary Report. <i>Neuropsychopharmacology</i> , 1998, 19, 445-448.	2.8	17
13	Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach. , 1998, 29, 142-147.		175
14	Effects of Ketamine on Thought Disorder, Working Memory, and Semantic Memory in Healthy Volunteers. <i>Biological Psychiatry</i> , 1998, 43, 811-816.	0.7	278
15	Challenges in patient management. <i>European Psychiatry</i> , 1998, 13, 219s-219s.	0.1	0
16	Cognitive Substrates of Thought Disorder, I: The Semantic System. <i>American Journal of Psychiatry</i> , 1998, 155, 1671-1676.	4.0	276
17	Effect of Acute Metabolic Stress on Pituitary-Adrenal Axis Activation in Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 1998, 155, 979-981.	4.0	72
18	Dopamine D ₂ Receptor Density and Personal Detachment in Healthy Subjects. <i>American Journal of Psychiatry</i> , 1998, 155, 1440-1442.	4.0	117

#	ARTICLE	IF	CITATIONS
19	Cognitive Substrates of Thought Disorder, II: Specifying a Candidate Cognitive Mechanism. American Journal of Psychiatry, 1998, 155, 1677-1684.	4.0	116
20	CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophrenia Research, 1997, 25, 123-129.	1.1	53
21	Apolipoprotein E ϵ 4 and clinical phenotype in schizophrenia. Lancet, The, 1997, 350, 930-931.	6.3	31
22	Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine. Biological Psychiatry, 1997, 42, 664-668.	0.7	185
23	Quantification of Amphetamine-Induced Changes in [¹¹ C]Raclopride Binding with Continuous Infusion. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 437-447.	2.4	237
24	Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics. Neuropsychopharmacology, 1997, 17, 141-150.	2.8	603
25	Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophrenia Research, 1996, 22, 215-222.	1.1	35
26	Idazoxan and Response to Typical Neuroleptics in Treatment-Resistant Schizophrenia. British Journal of Psychiatry, 1996, 168, 571-579.	1.7	128
27	Clozapine response and the 5HT _{2C} Cys23Ser polymorphism. NeuroReport, 1996, 7, 2100-2102.	0.6	78
28	Biologic Predictors of Clozapine Response in Schizophrenia. Psychiatric Annals, 1996, 26, 390-394.	0.1	4
29	Increased serum soluble interleukin-2 receptors in caucasian and Korean schizophrenic patients. Biological Psychiatry, 1994, 35, 767-771.	0.7	61
30	Spectrum of EEG abnormalities during clozapine treatment. Electroencephalography and Clinical Neurophysiology, 1994, 91, 205-211.	0.3	66
31	Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia. Schizophrenia Research, 1994, 12, 107-120.	1.1	49
32	Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophrenia Research, 1994, 13, 133-143.	1.1	57
33	Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. European Archives of Psychiatry and Clinical Neuroscience, 1993, 243, 7-10.	1.8	71
34	Clinical investigation of monoamine neurotransmitter interactions. Psychopharmacology, 1993, 112, S76-S84.	1.5	27
35	Adverse Effects of Antipsychotic Drugs. Drug Safety, 1993, 9, 429-436.	1.4	38
36	Autonomic effects of clozapine in schizophrenia: Comparison with placebo and fluphenazine. Biological Psychiatry, 1993, 34, 3-12.	0.7	72

#	ARTICLE	IF	CITATIONS
37	Beneficial Effects of Nalmefene Augmentation in Neuroleptic-Stabilized Schizophrenic Patients. <i>Neuropsychopharmacology</i> , 1993, 9, 111-115.	2.8	30
38	Idazoxan, an α_2 Antagonist, Augments Fluphenazine in. <i>Journal of Clinical Psychopharmacology</i> , 1993, 13, 264-267.	0.7	31
39	The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia. <i>British Journal of Psychiatry</i> , 1993, 162, 43-48.	1.7	283
40	Is the Mechanism of Prefrontal Hypofunction in Depression the Same as in Schizophrenia?. <i>British Journal of Psychiatry</i> , 1993, 162, 183-192.	1.7	119
41	Clinical and Biologic Response to Clozapine in Patients With Schizophrenia. <i>Archives of General Psychiatry</i> , 1992, 49, 345.	13.8	352
42	The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients. <i>Life Sciences</i> , 1991, 48, 1411-1416.	2.0	22
43	Maladaptive anticipatory saccades in schizophrenia. <i>Biological Psychiatry</i> , 1991, 30, 779-794.	0.7	55
44	Neurochemical and Neural Mechanisms of Positive and Negative Symptoms in Schizophrenia. <i>Modern Problems of Pharmacopsychiatry</i> , 1990, 24, 124-151.	2.5	16
45	Cerebrospinal Fluid and Plasma Monoamine Metabolites and Their Relation to Psychosis. <i>Archives of General Psychiatry</i> , 1990, 47, 641.	13.8	89
46	Drug trials and heterogeneity in schizophrenia: The mean is not the end. <i>Biological Psychiatry</i> , 1990, 28, 1021-1025.	0.7	13
47	Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia. <i>Psychiatry Research</i> , 1990, 33, 259-267.	1.7	7
48	Alprazolam-neuroleptic treatment in schizophrenia. <i>Schizophrenia Research</i> , 1989, 2, 215.	1.1	1
49	Specificity of plasma HVA response to dexamethasone in psychotic depression. <i>Psychiatry Research</i> , 1989, 29, 177-186.	1.7	17
50	Cerebral structure in borderline personality disorder. <i>Psychiatry Research</i> , 1989, 27, 111-115.	1.7	30
51	Suicidal behavior in depression: Relationship to noradrenergic function. <i>Biological Psychiatry</i> , 1989, 25, 341-350.	0.7	29
52	Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA. <i>Biological Psychiatry</i> , 1989, 25, 431-439.	0.7	25
53	Increased temporal lobe glucose use in chronic schizophrenic patients. <i>Biological Psychiatry</i> , 1989, 25, 835-851.	0.7	131
54	TRH-induced prolactin release in unipolar depressed patients and controls. <i>Journal of Psychiatric Research</i> , 1988, 22, 221-225.	1.5	3

#	ARTICLE	IF	CITATIONS
55	Plasma Homovanillic Acid as an Index of Central Dopaminergic Activity: Studies in Schizophrenic Patients. <i>Annals of the New York Academy of Sciences</i> , 1988, 537, 339-346.	1.8	27
56	Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers. <i>Psychiatry Research</i> , 1988, 25, 187-194.	1.7	65
57	The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. <i>Life Sciences</i> , 1988, 43, 1141-1150.	2.0	48
58	Single-dose naloxone acutely reduces eating in obese humans: Behavioral and biochemical effects. <i>Biological Psychiatry</i> , 1988, 24, 483-487.	0.7	28
59	A central 6-hydroxydopamine lesion prevents fluphenazine-induced increase in plasma homovanillic acid. <i>Brain Research Bulletin</i> , 1988, 20, 567-571.	1.4	10
60	Urinary-free cortisol in depressed patients and controls: relationship to urinary indices of noradrenergic function. <i>Psychological Medicine</i> , 1988, 18, 93-98.	2.7	18
61	Clinical and Biochemical Effects of Verapamil Administration to Schizophrenic Patients. <i>Archives of General Psychiatry</i> , 1987, 44, 113.	13.8	57
62	Plasma norepinephrine responses to cold challenge in depressed patients and normal controls. <i>Psychiatry Research</i> , 1987, 21, 161-168.	1.7	40
63	Cerebrospinal fluid corticotropin-releasing hormone in depression: Relationship to noradrenergic function. <i>Psychiatry Research</i> , 1987, 20, 229-237.	1.7	47
64	Prednisone decreases CSF somatostatin in healthy humans: Implications for neuropsychiatric illness. <i>Life Sciences</i> , 1987, 41, 1929-1933.	2.0	27
65	Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. <i>Life Sciences</i> , 1987, 40, 2031-2039.	2.0	132
66	Chronic corticosterone administration in rats: Behavioral and biochemical evidence of increased central dopaminergic activity. <i>European Journal of Pharmacology</i> , 1986, 122, 329-338.	1.7	69
67	Pre- and post-dexamethasone plasma ACTH levels in depressed patients and normal controls. <i>Journal of Affective Disorders</i> , 1986, 10, 95-99.	2.0	34
68	Endogenous opioid regulation of hypothalamo-pituitary-adrenal axis activity in schizophrenia. <i>Biological Psychiatry</i> , 1986, 21, 366-373.	0.7	15
69	Urinary excretion of free tyramine and of norepinephrine and its metabolites in unipolar depressed patients. <i>Biological Psychiatry</i> , 1986, 21, 221-224.	0.7	9
70	Neurobiologic Correlates. <i>Annals of the New York Academy of Sciences</i> , 1986, 487, 189-196.	1.8	33
71	Responses to Corticotropin-Releasing Hormone in the Hypercortisolism of Depression and Cushing's Disease. <i>New England Journal of Medicine</i> , 1986, 314, 1329-1335.	13.9	762
72	Symptoms and EEG Findings in the Borderline Syndrome. <i>International Journal of Psychiatry in Medicine</i> , 1986, 15, 201-211.	0.8	83

#	ARTICLE	IF	CITATIONS
73	Urinary monoamines and monoamine metabolites in subtypes of unipolar depressive disorder and normal controls. <i>Psychological Medicine</i> , 1986, 16, 541-546.	2.7	50
74	Longitudinal Measurement of Plasma Homovanillic Acid Levels in Schizophrenic Patients. <i>Archives of General Psychiatry</i> , 1986, 43, 669.	13.8	310
75	Pre-Menopausal and Post-Menopausal Depressed Women. <i>Australian and New Zealand Journal of Psychiatry</i> , 1986, 20, 464-469.	1.3	6
76	Studies of the Endogenous Opioid System in the Human Stress Response. , 1986, , 35-45.		9
77	CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. <i>Psychological Medicine</i> , 1985, 15, 335-340.	2.7	68
78	Naloxone Reduces Food Intake in Humans. <i>Psychosomatic Medicine</i> , 1985, 47, 132-138.	1.3	47
79	Tyramine pressor sensitivity changes during deprenyl treatment. <i>Psychopharmacology</i> , 1985, 86, 432-437.	1.5	83
80	Positron Emission Tomography in Schizophrenic Patients with and without Neuroleptic Medication. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1985, 5, 201-206.	2.4	175
81	Chronic clorgyline and pargyline increase apomorphine-induced stereotypy in the rat. <i>Pharmacology Biochemistry and Behavior</i> , 1985, 23, 921-925.	1.3	14
82	Lithium Potentiation of Imipramine in Treatment Resistant Depression. <i>British Journal of Psychiatry</i> , 1985, 147, 582-583.	1.7	11
83	High-dose naloxone administration in chronic schizophrenia. <i>Biological Psychiatry</i> , 1985, 20, 573-575.	0.7	21
84	Life events in depression Relationship to subtypes. <i>Journal of Affective Disorders</i> , 1985, 9, 143-148.	2.0	44
85	Dexamethasone increases plasma HVA but not MHPG in normal humans. <i>Psychiatry Research</i> , 1985, 16, 101-109.	1.7	43
86	Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. <i>Psychiatry Research</i> , 1985, 15, 281-292.	1.7	112
87	Hormonal effects of high dose naloxone in humans. <i>Neuropeptides</i> , 1985, 6, 373-380.	0.9	23
88	Biologic tests in depression. <i>Psychosomatics</i> , 1984, 25, 443-451.	2.5	28
89	Endocrine effects of the cold pressor test: Relationships to subjective pain appraisal and coping. <i>Psychiatry Research</i> , 1984, 12, 227-233.	1.7	50
90			

#	ARTICLE	IF	CITATIONS
91	High-dose naloxone affects task performance in normal subjects. <i>Psychiatry Research</i> , 1983, 8, 127-136.	1.7	49
92	The relationship of plasma cortisol and β -endorphin immunoreactivity to surgical stress and postoperative analgesic requirement. <i>General Hospital Psychiatry</i> , 1983, 5, 93-98.	1.2	22
93	Extreme Elevations in Plasma Norepinephrine Associated with Decreased β -Adrenergic Responsivity in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 1983, 3, 39-41.	0.7	12
94	The Role of the Endogenous Opioid System in the Human Stress Response. <i>Psychiatric Clinics of North America</i> , 1983, 6, 457-471.	0.7	39
95	Selective and Nonselective Monoamine Oxidase Inhibitors. <i>Archives of General Psychiatry</i> , 1982, 39, 535.	13.8	34
96	Effects of Fentanyl on the Response of Plasma Beta-Endorphin Immunoreactivity to Surgery. <i>Anesthesiology</i> , 1982, 57, 468-472.	1.3	38
97	Short-term Naloxone Administration in Schizophrenic and Manic Patients. <i>Archives of General Psychiatry</i> , 1982, 39, 313.	13.8	100
98	Stress-induced plasma beta-endorphin immunoreactivity may predict postoperative morphine usage. <i>Psychiatry Research</i> , 1982, 6, 7-12.	1.7	66
99	Response of plasma beta-endorphin immunoreactivity to d-amphetamine and placebo in schizophrenic patients. <i>Psychiatry Research</i> , 1982, 7, 171-178.	1.7	9
100	Physiological effects of high dose naloxone administration to normal adults. <i>Life Sciences</i> , 1982, 30, 2025-2031.	2.0	59
101	Cardiovascular changes in response to selective monoamine oxidase inhibition in the rat. <i>European Journal of Pharmacology</i> , 1982, 80, 155-160.	1.7	14
102	ENDORPHINS IN THE CEREBROSPINAL FLUID OF PSYCHIATRIC PATIENTS. <i>Annals of the New York Academy of Sciences</i> , 1982, 398, 399-412.	1.8	19
103	CLINICAL AND EXPERIMENTAL STUDIES OF STRESS AND THE ENDOGENOUS OPIOID SYSTEM. <i>Annals of the New York Academy of Sciences</i> , 1982, 398, 424-432.	1.8	6
104	Endorphins and Affective Illness. , 1982, , 375-397.		3
105	Episodic secretion of opioid activity in human plasma and monkey CSF: Evidence for a diurnal rhythm. <i>Life Sciences</i> , 1981, 28, 931-935.	2.0	60
106	Dextroamphetamine infusions in normals result in correlated increases of plasma β -endorphin and cortisol immunoreactivity. <i>Life Sciences</i> , 1981, 29, 1243-1247.	2.0	29
107	Surgical stress in humans is accompanied by an increase in plasma beta-endorphin immunoreactivity. <i>Life Sciences</i> , 1981, 29, 1249-1254.	2.0	132
108	Effect of carbamazepine on CSF opioid activity: Relationship to antidepressant response. <i>Psychiatry Research</i> , 1981, 5, 59-66.	1.7	12

#	ARTICLE	IF	CITATIONS
109	Relationship between urinary free cortisol and CSF opioid binding activity in depressed patients and normal volunteers. <i>Psychiatry Research</i> , 1981, 5, 87-93.	1.7	19
110	BEHAVIOURAL EFFECTS AFTER HIGH DOSE NALOXONE ADMINISTRATION TO NORMAL VOLUNTEERS. <i>Lancet, The</i> , 1981, 318, 1110.	6.3	73
111	Measurement of Endorphins in CSF. <i>Modern Problems of Pharmacopsychiatry</i> , 1981, 17, 246-262.	2.5	8
112	Pharmacological Challenges to the Endogenous Opioid System in Affective Illness. <i>Journal of Clinical Psychopharmacology</i> , 1981, 1, 223-231.	0.7	10
113	Tyramine infusions and selective monoamine oxidase inhibitor treatment. <i>Psychopharmacology</i> , 1981, 74, 4-7.	1.5	44
114	Tyramine infusions and selective monoamine oxidase inhibitor treatment. <i>Psychopharmacology</i> , 1981, 74, 8-12.	1.5	30
115	Naloxone effects on β -endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers. <i>Psychopharmacology</i> , 1981, 74, 125-128.	1.5	87
116	Presynaptic noradrenergic regulation during depression and antidepressant drug treatment. <i>Psychiatry Research</i> , 1980, 3, 93-105.	1.7	91
117	PLASMA OPIOID ACTIVITY IN MANIC-DEPRESSIVE ILLNESS. <i>Lancet, The</i> , 1980, 315, 937.	6.3	38